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Abstract
Background: Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is an inherited disease mainly found in
young people causing malignant arrhythmias which can result in sudden cardiac death. Due to unspecific
symptoms the diagnosis of ARVC is still challenging and requires clinical testing and expert knowledge. Genetic
testing of index patients is helpful in the primary diagnosis and further testing of family members may allow for
prevention of sudden cardiac death.
Case presentation: We report a case of newly diagnosed ARVC where genetic testing identified a novel familial
frame-shift mutation in the PKP2 gene. Screening of the family members identified both children and the father as
mutation carriers following an autosomal-dominant inheritance pattern.
Conclusion: Our findings emphasize the importance of genetic family screening after the identification of a causative
mutation in an index case.
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Background
Arrhythmogenic Right Ventricular Cardiomyopathy
(ARVC) is a hereditary cardiac disease that predominantly
affects the right and possibly the left ventricle and is
pathologically characterized by progressive fibrofatty
replacement of myocardium [1]. Clinically cardiac rhythm,
i.e., palpitations, syncope and sudden cardiac death (SCD),
or cardiac function, i.e., right- or bi-ventricular heart fail-
ure resembling dilated cardiomyopathy, may be affected.
The diagnosis is based on the 2010 Task Force criteria
including characteristic electrocardiographic, arrhythmic,
structural and/or histological abnormalities [2]. The
prevalence is estimated to be 1:1000 to 1:5000 with a
mean age at diagnosis of 31 years (±13; range 4–64 years)
[3]. ARVC is acknowledged to be a leading cause of
ventricular arrhythmias and SCD in young, often athletic
subjects below the age of 35 years [1, 2]. As much as 30 –
50 % of ARVC patients have a positive family history and
ARVC most commonly follows an autosomal-dominant
inheritance. However, incomplete penetrance and highly
variable and age-dependent disease expression are ob-
served [1].
Case presentation
A 43-year-old female presented with shortness of
breath, chest discomfort and light-headedness while
cross-country skiing. She was able to call the rescue
service herself and upon arrival they detected a wide
QRS complex tachycardia with left bundle branch block
morphology and inferior axis at 190 bpm that was
terminated by administration of 50 mg Ajmalin i.v.
(Fig. 1a). In stable condition the patient was transferred
to our emergency room for further evaluation. Medical
history included repeated episodes of similar symptoms
upon physical exertion, yet no syncope. The family his-
tory was remarkable of a survived sudden cardiac arrest
of the patient’s father at the age of 86 years and recur-
rent syncopes during exercise of the patient’s daughter.
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The resting 12-lead ECG displayed T-wave inversion
in leads V1-4 in the absence of bundle branch block
configuration (Fig. 1b). Laboratory analysis showed
mildly elevated troponin T. Echocardiography showed
normal size and function of the left ventricle. However,
the right ventricle (RV) was significantly enlarged with
reduced function (Fig. 2a). Cardiac MRI displayed a re-
duced RV ejection fraction of 27 % with moderate RV
enlargement and increased RV end-diastolic volume
(128 ml) (Fig. 2b, c), as well as akinesia of the apical RV
posterior wall with late enhancement in this area
(Fig. 2d). The coronary angiogram was normal. 12 lead-
Holter monitoring revealed numerous premature ectopic
ventricular beats (>7000) and three episodes of sustained
ventricular tachycardia around 200 bpm the longest last-
ing over 20 min with left bundle branch block configur-
ation originating from the RV outflow tract (RVOT). In
the electrophysiological study, 3D electroanatomic volt-
age mapping showed low voltage areas in the apical and
basal inferior RV as well as the lateral and medial RV
outflow tract. Isoproterenol infusion as well as pro-
grammed ventricular stimulation induced the clinically
documented ventricular tachycardia (VT) as well as 3
other forms of RV-VT. Radiofrequency energy ablation
guided by voltage and activation mapping successfully
eliminated all induced VTs and reached non-inducibility
of ventricular arrhythmias. Taken together the definite
clinical diagnosis of late-onset arrhythmogenic right
ventricular cardiomyopathy (ARVC) was made according
to the modified Task Force criteria by Marcus et al. [2].
The patient fulfilled two major criteria of ARVC (MRI
pathology, repolarization abnormalities) and one minor
criterion (arrhythmia).
During the following days ventricular tachycardia
could neither be recorded in repeated Holter monitor-
ing nor induced by controlled exercise stress testing.
Nevertheless, we recommended the implantation of an
automated implantable cardiac defibrillator (ICD) for
secondary prophylaxis of sudden cardiac death, which
was initially refused by the patient. The patient agreed,
however, to conduct genetic testing of common ARVC
genes for eventual substantiation of the diagnosis.
While DNA exon sequencing of the ARVC genes
desmoglein 2 (DSG2), desmoplakin (DSP), ryanodine re-
ceptor 2 (RYR2), transmembrane protein 43 (TMEM43),
desmocollin 2 (DSC2), junction plakoglobin (JUP) and
transforming growth factor beta 3 (TGFB3) showed no
pathological findings, sequencing of the plakophilin-2
(PKP2) gene identified a new variant in exon 7 (performed
at the Synlab, Mannheim, Germany). This heterozygous
c1664delT deletion mutation has not yet been described
in the literature (HGMD Professional 2014.1). However, a
pathogenic effect of this mutation is very likely, since the
frame-shift p.F555Sfs*8 prematurely terminates translation
which probably leads to degradation of RNA or compos-
ition of an altered protein (Fig. 3a, b). Both mechanisms
would result in loss of function of the mutated allele. Con-


























Fig. 1 a 12-Lead ECG of the index patient (paper speed 25 mm/s) showing ventricular tachycardia with left bundle branch block morphology
and inferior axis. b Resting 12-Lead ECG upon admission to our hospital showing sinus rhythm (paper speed 50 mm/s). T-wave inversion is
present in V1-V4
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implantation and a single-chamber ICD was successfully
implanted. In the 6-months follow-up no sustained or
non-sustained ventricular tachycardia was recorded in the
ICD memory.
Predictive genetic testing of first-degree family members
of the index patient for the new PKP2 mutation disclosed
the familial heterozygous mutation in both children (ages
13 and 16) and the father of the patient. Neither her
mother, nor her sister and her aunt were carriers of the
mutation (Fig. 3c, Table 1). All carriers of the mutation
underwent a comprehensive cardiological work-up includ-
ing 12-lead ECG, exercise stress test, Holter monitoring,
echocardiography and MRI of the heart (performed at
Deutsches Herzzentrum München, Universitätsklinikum
München-Großhadern, Germany).
The daughter showed an orthostatic reaction after stress
testing resulting in dizziness and pre-syncopy but no ar-
rhythmias were detected during this episode. At present,
the remaining cardiological examinations were normal.
The son presented with an epsilon potential in lead V1 in
the resting ECG. The results of all other tests showed cur-
rently no abnormal findings. Nevertheless, with two major
criteria being present, ARVC was diagnosed in the son.
Both children were recommended to refrain from exces-
sive physical exercise and to perform semi-annual cardio-
logic check-ups. The 91-year old father of the index
patient, currently still in good health, had a long-standing
medical history of cardiac diseases, including sick sinus
syndrome, implantation of a biologic aortic valve at the
age of 81 and one episode of ventricular tachycardia that
A)
B) C) D)
Fig. 2 a Echocardiography of index patient shows dilatation of the right ventricle. RVD1 (basal right ventricle): 42.5 mm (Mean value (95 % CI) 33
(31–35 mm)). RVD2 (mid right ventricle) 32.7 mm (Mean value (95 % CI) 28 (23–33 mm)). RVD3 (base to apex length) 58.6 mm (Mean value (95 %
CI) 71 (67–75 mm)). Mean values (95 % CI) according to Rudski et al. [9]. b Cardiac MRI of the index patient reveals moderate enlargement of the
right ventricle with an enddiastolic volume of 186 ml (standard value female 140 ± 37 ml) and (c) endsystolic volume of 135 ml (standard value
female 52 ± 22 ml) resulting in a highly reduced ejection fraction of 27 % (standard value female 64 ± 7 %) Furthermore, the apical posterior wall
of the right ventricle showed akinesia and (d) late gadolinium enhancement identified apical fibrosis (yellow arrows) in the 4-chamber view.
Standard values according to Hudsmith et al. [10]
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was successfully terminated with i.v. amiodarone at the
age of 86, when he declined the implantation of an ICD.
Echocardiography showed significant dilatation of the
right ventricle with severely reduced function (TAPSE =
7 mm). Upon MRI the right ventricular ejection fraction
was severely reduced (20 %) with akinesia and fibrosis of
the lateral wall. Therefore, the diagnosis of ARVC was
made.
Discussion
We report a case of a 43-year old female with newly
diagnosed ARVC in whom genetic testing identified a
novel frame-shift mutation in the PKP2 gene. Although
the clinical diagnosis was established according to the
2010 Task Force criteria, the patient was reluctant to
undergo ICD implantation, since she had not suffered
from severe symptoms and felt that the intervention posed
a substantial change to her daily life. In our case genetic
testing was able to substantiate the diagnosis by the find-
ing of a new frame-shift mutation in the PKP2 gene and
to convince the patient of the need for the ICD implant-
ation. Moreover, a comprehensive family screening de-
tected the mutation in both of her children and her father
following an autosomal-dominant inheritance. The disease
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Fig. 3 Electropherogram curves and sequences of (a) the wildtype sequence and (b) the index patient: The index patient shows the frameshift
mutation c.1664delT (p.F555Sfs*8) in the PKP2-gene. c Pedigree of the index patient (II.2) displaying an autosomal dominant inheritance pattern.
Her father (I.2) is also diagnosed with ARVC and both children (III.1 and III.2) are mutation carriers, the son (III.2) fulfills the 2010 Task Force criteria
of ARVC and is diagnosed with the disease
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was also present in an advanced state in the father, and di-
agnosed in an early asymptomatic stage in the son,
whereas the daughter had currently normal test results.
While no sensible medical recommendations arose for the
nonagenarian father, the teenage children of the patient
are now confronted with the fact that they are asymptom-
atic disease and mutation carriers respectively. As a result,
lifestyle modifications such as restraint from exhausting
physical activity and cardiologic check-ups on a regular
basis are warranted.
Genetic testing in ARVC
According to the Heart Rhythm Society/European Heart
Rhythm Association’s Expert Consensus Statement genetic
testing in ARVC can be useful for patients satisfying the
2010 Task Force diagnostic criteria and may be considered
for patients with possible ARVC (1 major or 2 minor cri-
teria), while it is not recommended for patients with only a
single minor criterion. Mutation-specific genetic testing is
recommended for family members after the identification
of a causative mutation in an index case [4]. To date,
mutations in eight genes are known to cause the disease
(PKP2, DSG2, DSP, DSC2, RYR2, TGFB3, JUP, TMEM43),
with six of them encoding for proteins with importance for
desmosomal structure or function (PKP2, DSG2, DSP,
DSC2, JUP, TMEM43) [5]. Mutations in PKP2 are most
common ranging from 10 – 78 % in ARVC patients [6, 7].
The overall yield of a current generation genetic test for a
patient with the clinical diagnosis of ARVC approximates
50 % [7]. However, the frequency of rare variants in ARVC
susceptibility genes in healthy volunteers, the so-called
background rate of genetic variability, is estimated with
16 %, meaning that 1 in 6 healthy individuals would meet
current criteria for a positive ARVC genetic test result [7].
Understanding the genetic variability including the import-
ance of the genetic background mutation rate is important
for the interpretation of a genetic test result. For compari-
son, in long-QT syndrome the rate of “mutations” without
clinical phenotype in the three most frequently involved
genes KCNQ1, KCNH2, and SCN5A is only 5 % [8]. Ideally,
patients should be referred to specialized centers to per-
form the genetic test and test results have to be interpreted
Table 1 Results of genetic testing and clinical criteria (major, minor) for the diagnosis of ARVC of the index patient and the tested family
members. According to the 2010 Task Force criteria diagnosis of ARVC can be made by presence of the following criteria: 2 major criteria
or 1 major?+?2 minor criteria or 4 minor criteria (from different categories) [2]. The criteria for diagnosis were fulfilled in the index patient
(II.2), her father (I.2) and her son (III.2), all marked in blue. RV right ventricle; in brackets number of criteria present
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in light of clinical test results. Moreover, mutation charac-
teristics seem to play a role in determining the probability
of pathogenicity. Kapplinger et al. [7] found that radical
mutations in ARVC susceptibility genes, such as in-frame
and frame-shift insertions and deletions, splice junction,
and nonsense mutations, are strongly associated with the
disease (42.9 % in ARVC cases vs. 0.47 % in healthy con-
trols, p < 9.8 × 10−44), whereas rare missense mutations are
less likely to be related to ARVC and should be interpreted
in the context of race and ethnicity, mutation location, and
sequence conservation [7]. Radical mutations, as the frame-
shift mutation in our patient, are found in approximately ¾
of mutation-positive ARVC cases [7]. Despite the deleteri-
ous nature of this novel frame-shift mutation on the gene
product the age of diagnosis in our patient and that of her
father in particular is high. One can speculate whether this
specific mutation goes along with a late-onset of symptoms
and is comparatively “benign”, or whether other factors,
such as genetic background and external influences (e.g.,
physical activity) affect the course of the disease. However,
it is known that the presentation of ARVC can be highly
variable even within families, which is of particular import-
ance for the patient’s clinically asymptomatic children with
positive genetic testing in whom preventive measures
should be taken. In general our case suggests that genetic
evaluation in ARVC can be helpful to establish the definite
diagnosis and to influence clinical decision making, but
should be viewed as one component of comprehensive clin-
ical assessment and never replace clinical judgment.
Conclusion
We report a case of newly diagnosed ARVC where genetic
testing identified a novel familial frame-shift mutation in
the PKP2 gene. Although not meant to override clinical
judgment, the case shows that in index cases genetic testing
can be helpful to establish the definite diagnosis and to
guide treatment considerations. Among family members
mutation-specific genetic cascade screening has diagnostic,
prognostic and therapeutic implications. Interpretation of
test results for ARVC is challenging and referring patients
to specialty centers is strongly encouraged.
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